Division of Baxter International Inc.
Latest From SuppreMol GmbH
Basel-based BioMedPartners has launched a new CHF75m venture capital fund, BioMedInvest III, boosting financing opportunities for startups and mid-sized biotechs in the sparse European market.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.
Baxter's Bioscience Business has acquired SuppreMol for €200m in what the privately-held German firm's CEO called "a good day for both companies."
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Western Europe
- Parent & Subsidiaries
- Baxter International Inc.
- Senior Management
Peter Buckel, CEO
Michael Kring, CFO
Peter Sondermann, PhD, CSO
- Contact Info
Phone: (49) 89 309050 68 0
Am Klopferspitz 19
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.